Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 04, 2015 12:15 AM ET

Life Sciences Tools and Services

Company Overview of CyDex Pharmaceuticals, Inc.

Company Overview

CyDex Pharmaceuticals, Inc. develops and licenses Captisol, a drug formulation technology that enables new product development by improving the solubility, stability, bioavailability, and dosing of active pharmaceutical ingredients (APIs). Its Captisol drug formulation technology is designed to maximize safety by eliminating the damaging effects produced by the parent beta-cyclodextrin; and enable an aqueous formulation for various water insoluble APIs as oral, nasal, topical, ophthalmic, or liquid-presented medications. The company also has license and supply agreements in place with various pharmaceutical companies worldwide with Captisol-enabled product candidates. In addition, it offers ...

10513 West 84th Terrace

Lenexa, KS 66214

United States

Founded in 1993

27 Employees

Phone:

913-685-8850

Fax:

913-685-8856

Key Executives for CyDex Pharmaceuticals, Inc.

Executive Vice President
Senior Director of Business Development and Investor Relations
Vice President of Business Development & Marketing
General Manager
Age: 48
Director of Corporate Development
Compensation as of Fiscal Year 2015.

CyDex Pharmaceuticals, Inc. Key Developments

Marinus Pharmaceuticals Seals Deal with CyDex Pharmaceuticals, Inc. for Clinical Use of Captisol

Marinus Pharmaceuticals signed an agreement with CyDex Pharmaceuticals for the clinical use of Captisol. Captisol is a uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. MRNS said it plans to use Captisol to evaluate ways to optimize its intravenous dose form of ganaxolone.

Similar Private Companies By Industry

Company Name Region
Vince & Associates Clinical Research Inc. United States
Sequoia Sciences, Inc. United States
Regenerative Medical Solutions, Inc. United States
Tanner Pharma Group, LLC United States
Radux Devices, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CyDex Pharmaceuticals, Inc., please visit www.captisol.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.